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Introduction: The Munich Dysphagia Test for Parkinson’s disease (MDT-PD) was initially
developed and validated in the German population as a highly sensitive and specific
self-reported screening questionnaire to detect early oropharyngeal symptoms and
aspiration risk in patients with idiopathic Parkinson’s disease (iPD). In order to make
this tool accessible for prevention in the French speaking populations worldwide, we
performed the first French translation and provide a linguistic and psychometric validation
in the unique multilingual environment of the Luxembourg Parkinson’s Study.
Methods: We performed the translation of the MDT-PD into French according to WHO
guidelines and subsequently performed the linguistic validation including native speakers.
For psychometric validation, 46 patients with parkinsonism from Luxembourg and the
Greater Region without severe cognitive impairment were recruited in the frame of the
Luxembourg Parkinson’s Study. All patients were fluent in French and German completed
the MDT-PD in both languages (three times in total).
Results: Linguistic and psychometric validation of the French MDT-PD was reflected
by a high test-retest (10/26 questions with K > 0.6 and 10/26 with 0.4 <K ≤ 0.6)
and language reliability (12/26K > 0.6 and 8/26 0.4 < K ≤ 0.6), with an internal
consistency for the French (Cronbach’s alpha 0.84) and German version (0.87); strong
item collinerarity strengthens the internal consistency. No significant differences between
MDT-PD score distribution and clinical parameters assessing, for example, disease
progression, motor state, or cognition has been observed.
Conclusion: Based on a multilingual approach in the Luxembourg Parkinson Study,
we validated the translation of the first French MDT-PD as a non-invasive tool for early
detection of dysphagia in patients with parkinsonism. The unexpectedly high number of
positively screened patients at earlier disease stages indicate options for new prevention
strategies in large French speaking populations worldwide. Diagnostic validation using
clinical and endoscopic swallowing evaluation will be continued soon.
Keywords: parkinsonism, swallowing problems, dysphagia, patient questionnaire, early detection, linguistic and
psychometric validation
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HIGHLIGHTS
- First French version of MDT-PD questionnaire provides a
non-invasive and easy to administer screening tool for the
French speaking population.
- Study was conducted among the patients included in
the Luxembourg Parkinson’s Study with long term annual
follow-up and deep clinical, genetic, and multi-omics
phenotypisation that will allow for further analysis and
prospective follow-up of the analyzed patients.
- Linguistic and psychometric validation resulted in both high
reliability properties and high language validity.
- Highlighting the value of MDT-PD implementation as it
allows an early detection of oropharyngeal symptoms as well
as aspiration risk and therefore supports early dysphagia
treatment, preventing severe clinical complications, and
maintaining patients’ quality of life.
- The observation of a H&Y stage independent presence
of swallowing problems strengthening the hypothesis of
dysphagia as an early axial symptom in PD.
INTRODUCTION
Oropharyngeal dysphagia is a frequent symptom in both
idiopathic Parkinson’s disease (PD) and atypical forms of
parkinsonism (aPS). Due to an early loss of oropharyngeal
sensibility and an impaired self-awareness a pooled prevalence
for PD is reported to be 35% (95% CI 28–41) when simple self-
assessment was performed, whereas 82% (95% CI 77–87) when
objective instrumental measures were taken into account (1).
Contrary to the generally excepted belief that dysphagia
occurs in the advanced stages of PD only, a convincing body of
evidence suggests it to be an early symptom with non-negligible
consequences (2) such as malnutrition, weight loss, dehydration,
or aspiration pneumonia with severe impact on prognosis and
quality of life. In order to prevent the clinical complications,
a timely diagnostic approach and professional care is essential,
thus an accessible non-invasive early screening for dysphagia is
required (3, 4).
Besides the currently applied gold standard examination
with flexible endoscopic evaluation of swallowing (FEES)
or videofluoroscopic swallowing study (VFSS) to diagnose
dysphagia, there are up to date only two validated dysphagia
questionnaires available specially adapted for PD, the Munich
Dysphagia Test-Parkinson’s Disease [MDT-PD (4)] and the
Swallowing Disturbance questionnaire [SDQ, (5)]. While the
SDQ only allows to screen for severe swallowing impairment with
aspiration, the MDT-PD was developed among 187 individuals
in order to screen for the presence of beginning oropharyngeal
symptoms, and to assess the risk for laryngeal aspiration in PD
patients (6, 7). TheMDT-PD is considered to be a highly sensitive
and specific weighted self-reporting outcome questionnaire (8).
With respect to the screening results, recommendations and
indications for further instrumental diagnostics and appropriate
medical therapies can be provided (cf. Supplement 1, Table 1.1
or directly on the MDT-homepage/web application www.mdt-
parkinson.com).
The questionnaire contains 26 items, which all have
been previously tested for reliability and validity. A short-
form description is given in Supplement 1, Table 1.2. It has
been cross-nationally translated into other languages including
English, however yet there was no French version of the
questionnaire available, although 274 million people worldwide
from 29 countries use French in their daily life.
The objective of this work was to deliver a first translated
version of MDT-PD in French and to determine its validity in
the multilingual Luxembourgish population where participants
were recruited in the frame of the Luxembourg Parkinson’s
Study (9). The goal of the study was (i) a linguistic and
(ii) a psychometric validation of the French version of MDT-
PD questionnaire assessing test-retest and language reliability
properties, and construct validity with the focus on patients
diagnosed with PD as well as aPS.
MATERIALS AND METHODS
Study Population and Design
The subjects enrolled in this study have been recruited in
the scope of the Luxembourg Parkinson’s study, a nation-
wide, monocentric, descriptive, observational, longitudinal-
prospective cohort study with an annual follow-up of patients (9).
All the subjects have signed a written informed consent, and
the collection has been approved by the National Ethics Board
(CNER Ref: 201407/13) and Data Protection Committee (CNPD
Ref: 446/2017).
Additionally, a clinical steering committee composed of
different health professionals from Luxembourg involved
in PD care has been appointed and supervises the
recruitment procedures.
To be included in the study, all subjects must meet either the
UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic
Criteria (10, 11) for PD or the criteria defined for the
respective atypical forms of parkinsonism, including progressive
supranuclear palsy (PSP) (12, 13), multiple system atrophy
(MSA) (12), corticobasal syndrome (CBS) (13), or a secondary
form of parkinsonism, vascular parkinsonism (VP) (14), based
on internationally established criteria. Furthermore, participants
must speak fluently French for the ones implicated in the
linguistic validation phase and additionally German, for the
group implicated in the psychometric validation phase.
As the MDT is a self-reporting questionnaire, participants
with a significant cognitive impairment as defined by a MoCA
score < 17 were excluded.
All subjects enrolled in the Luxembourg Parkinson’s Study
undergo a comprehensive clinical phenotyping including the
assessment of motor and non-motor aspects of PD, including
(but not limited to) Hoehn & Yahr staging, MDS-UPDRS I–
IV, cognitive assessment via MoCA and disease duration since
diagnosis. For more details on the study design and protocol cf.
Hipp et al. (9).
The MDT-PD French study has been divided into two
phases, (i) the translation and (ii) the validation including (a)
linguistic validation of the translation, and (b) the validation of
its psychometric aspects, namely test-retest reliability, language
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FIGURE 1 | Flowchart of study phases. MDT-PD, Munich Dysphagia Test–Parkinson’s Disease; CSA, Clinical Swallowing Assessment; FEES, Flexible Endoscopic
Evaluation of Swallowing; PPV, Positive Predictive Value.
reliability, internal consistency, and construct validity. In
a continuing third phase the diagnostic validation will be
performed separately using the gold standard of clinical and
endoscopic swallowing evaluation (cf. Figure 1).
Questionnaire Description
The questionnaire contains 26 items (Q1–261). Items Q1–Q23
are rated on a 0, 1, 2, and 3 scale, while Q24–26 are rated
1(Q1) I have difficulties with the chewing and swallowing of solid/fibrous/crumbly
food (e.g., apples, meat, cracker/chips).
(Q2) During meals, food/liquid escapes from the mouth (or the nose).
(Q3) I find it difficult to directly/quickly start the swallowing process when taking
in liquids or food.
(Q4) For the complete swallowing of food/liquids I need to swallow multiple times
in a row.
(Q5) Food residues remain in my mouth after swallowing.
dichotomously (0, 3). A detailed questionnaire overview is given
in Supplement 1.
(Q6) During the swallowing process, food gets stuck in my throat/esophagus
(maybe I even have to choke).
(Q7) During (or after) eating food I have to hawk/cough.
(Q8) During (or after) drinking liquids (or eating soup) I have to hawk/cough.
(Q9) It happens that I have difficulties breathing/a sense of suffocation when
swallowing food or liquids.
(Q10) Right after eating food/drinking liquids my voice has changed
(e.g., coated/weakened/“wet”/“gargling”).
(Q11) I have increased amount of saliva inmymouth/I swallowmy saliva too rarely
or I have general problems swallowing my saliva/drooling.
(Q12) I have a very dry mouth/not enough saliva.
(Q13) It happens that I cough or have trouble breathing because I have choked on
my saliva/saliva went into my trachea.
(Q14) I have problems swallowing pills.
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Phase I: Translation
In a first step, the German MDT-PD was translated into French
with a forward-backward method, by four translators complying
with the WHO guidelines for cross-national translations of
clinical questionnaires (15).
Study Group
The translation group included the copyright holder of the
original German test version (speech-language pathologist) and
four at least bilingual (fluently German and French speaking
at C2 level) experts, one of them with French as mother
tongue, including an epidemiologist, a neurologist and two
neuropsychologists. Additionally, a group of the Luxembourgish
association of speech therapists advised the translation group in
terms of technical terminology.
Procedure
The first step involved the forward translation by two translators
independently carried out the translation from the original
German version into French. Taking the two translations into
account, the same translators proceeded to create one consented
single version (V1).
The second step, namely the backward translation, consisted
in the independent translation into German of the V1, by the two
other translators. Here again, both experts proceeded to a joint
discussion in order to consent to a single German version (V2).
At the final step, the backward translation V2 was reviewed
by the copyright holder and the translators. At this point, both
versions V1 and V2 additionally peer-reviewed by a group of the
Luxembourgish association of speech therapists.
Phase II: Validation
Linguistic Validation
The preliminary French version, as a result of the translation
process, has been tested in a small sample of patients, in order
to verify that all the items were interpreted as expected by
the population.
(Q15) During the off-phases (off-drug-state/declining levodopa levels) I have more
difficulties to swallow.
(Q16) I avoid specific foods or textures that oftenmakeme choke (e.g., nuts, crumb
cake, liquid-filled pralines, and raw vegetable salads).
(Q17) It is difficult for me to hawk/cough after I choke in order to clear my throat.
(Q18) Nowadays, it takes me more time to eat than it used to (e.g., because I have
to chew longer/foods are longer in my mouth due to longer preparation time or
more careful swallowing).
(Q19) It happens that I get tired during meals (or even fall asleep) and don’t finish
chewing and swallowing my food.
(Q20) During meals I have to have liquids to “flush down” the food in order to be
able to better swallow.
(Q21) I can only swallow liquids in small lips.
(Q22) I have a reduced appetite or pleasure to eat than before (sense of taste and
smell are potentially affected).
(Q23) I have problems, such as heartburn/frequent burping, sense of lump in the
throat/esophagus, sense of pressure behind the breastbone.
(Q24) Within the last year I had a lung infection or unclear fever-infections.
(Q25) I involuntarily loose body weight.
(Q26) I drink <50 oz. of liquid during a given day (equal to suggested minimum
of 7–8 glasses/cups water, juice, tea, coffee, and soup).
Subjects
Apart from the general inclusion criteria of the Luxembourg
Parkinson’s Study and those mentioned above, the patients
must additionally speak French as mother tongue. With these
inclusion criteria, seven patients have been selected to undergo
the questionnaire for the linguistic validation.
Procedure
Selected patients were asked to complete the translated version
with the “thinking aloud” method. Once they had completed
the French preliminary version in front of the investigator, they
were asked to rephrase each item in their own words, and to
add comments or ask comprehension questions, if necessary.
Patients’ comments were recorded and analyzed qualitatively.
Psychometric Validation
The French version of the MDT-PD questionnaire that has
previously been validated linguistically was analyzed for test-
retest reliability, language reliability, internal consistency, and
construct validity. For more details, cf. Supplement 1, Table 3
that contains the final French MDT-PD version.
Subjects
The patients included had to meet the global study inclusion
criteria mentioned above, and additionally, as it is the case for
most of the Luxembourgish population, they needed to speak
fluently French and German. Furthermore, basic medication
should be steady during the test completions. Enrollment into the
study was performed consecutively.
Sample size
Calculations are based on Hong et al. (16), and an evaluation of
the agreement between both tests with a Kappa test.
Given the pooled subjectively estimated prevalence of
dysphagia of 35% (1) and an expected difference between two
proportions of agreement of 0.2 between test and retest, 40
responses to the questionnaire (at the second test) would enable a
proportion agreement of 0.65 under H0, a proportion agreement
of 0.85 under H1 and a Kappa value of 0.64 to be detected with a
power 0.80 (two-tailed α= 0.05). If the response rate is 100% the
minimal number of subjects should be 40.
Procedure
The German version of the MDT-PD questionnaire is already
included in the yearly visits of the Luxembourg Parkinson’s study.
The subgroup of this cohort (defined previously in the section
Phase II: Validation) were asked to complete the MDT-PD at
three different steps (cf. Figure 1). The linguistically validated
French MDT-PD questionnaire was sent home before the clinic
visit, and patients were asked to fill it out 5–7 days before the visit
(FR1). At the clinical visit, the second completion of the French
version was performed (FR2). At the date of their clinical visit, the
patients were given the German version and asked to fill it out 5–
7 days after the visit (GE). The date of completion was carefully
recorded on each questionnaire.
The intervals have been chosen in order to avoid that subjects
base their answers on the ones given at previous time points
(17, 18).
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General Statistical Methodology
Descriptive statistics were produced as means, standard
deviations for the quantitative variables, and as total numbers
and percentages for the categorical data, as appropriate to
describe the studied population. Chi2 and/or Freeman–Halton
test was used to evaluate differences of categorical variables
between groups.
Each of the completion versions (FR1, FR2, and GE), were
analyzed for internal consistency and construct validity. As for
internal consistency, questions were categorized by the amount
of change expected and were compared between the test and the
retest versions of the questionnaire. Cronbach’s alpha was used to
compare the French version to theGerman version. To determine
the strength of questionnaire item collinearity, variance inflation
factors (VIF) were calculated. Kendall’s tau coefficients (t) were
calculated to assess bivariate associations of subjects’ answers to
the MDT-PD items.
Concerning construct validity, to detect inconsistencies
between different conditions of PD, patients were categorized
in groups depending on diagnosed type of parkinsonism, H&Y
staging, disease duration, cognitive state evaluated by the MoCA
test, motor performance evaluated by the MDS-UPDRS III and
difference in the MDT score compared2.
FR1 and FR 2 were compared to analyze test-retest reliability,
and FR1 and GE, respectively, FR2 and GE were compared to
assess language reliability.
Test-retest and language reliability were estimated for
categorical questions using percentage agreement and Kappa or
Krippendorff ’s alpha (KALPHA) values3.
Using the FR2 data, exploratory analyses were performed
by using interesting questions to create groups of comparison.
Patient profiles were then compared. Cohen’s Kappa and/or
KALPHA (19, 20) was used to evaluate concordance.
RESULTS
Results Phase I
Members of the translation group performedmodifications based
on the feedback of the reviewer and the speech therapists. The
modifications concerned technical terms (e.g., avaler instead
of déglutir).
The forward-backward translation method has resulted in
a preliminary French version that was agreed on by the four
members of the translation group.
2A Cronbach alpha > 0.8 was considered as good, >0.9 excellent, while alpha <
0.7 meant very unreliable results.
3Intraclass correlation coefficient was estimated for discrete data. Cohen’s Kappa
and KALPHA coefficients are reliability measures developed to evaluate the
agreement among observers, coders, judges, raters, annotators or measuring
devices. While the Kappa applies only to squared tables (2 × 2, 3 × 3, . . . ),
KALPHA can be used when there are some unmeasured categories. Good
agreement is considered for a Kappa > 0.8 and Alpha > 0.8. Alpha > 0.667 and
<0.800 is moderate agreement while below 0.667 agreement is discarded. Kappa<
0.7 is considered as bad agreement.
Results Phase II
Linguistic Validation
All subjects completed the French MDT-PD successfully. The
sample included six patients with IPD and one patient with PSP.
Mean age was 66.4 ± 11.5 years, mean H&Y stage was 2.2 ± 0.7,
mean MDS-UPDRS III was 35.4 ± 13, and mean MoCA score
was 25.1± 2.6.
The individual reformulations of the items reflected all the
intended meaning. Of the 26 items, three items only (Q3, 19, and
24) were addressed by two patients. The comments concerned
scaling of the trouble, but not the interpretation of the item.
As this is related to the global structure of the original German
version, it was not changed. Consequently, nomodification to the
initial version was required.
In conclusion, we delivered a linguistically valid French
version of the MDT-PD questionnaire in a French population,
enabling us to undergo a psychometric validation. Even if the
smaller sample size could reduce variability in the feedback, the
small amount of comments and the high rate on convergent
interpretation by all the subjects gave sufficient arguments that
the version provided is linguistically valid.
Psychometric Validation
Sample description
In total, 46 patients have been recruited from the Luxembourg
Parkinson’s Study cohort fulfilling the inclusion criteria for
validation purpose as mentioned above.
Sex ratio was 37/9 (M/F). The mean MDT was similar at the
three test versions (p= 0.9354) (cf. Table 1). Additional details of
the samples are given in Supplement 2.
Thirty-nine patients were diagnosed with IPD, while the
remaining patients had a diagnosis of aPS or secondary
parkinsonism, namely PSP (n = 3), CBS (n = 1), and VP (n =
1). The two remaining patients had a parkinsonism that had not
yet been defined.
TABLE 1 | Characteristics of the sample expressed in means for the clinical data
and MDT-PD results.
Variable N Missing data
(number of
participants)
Mean Std.
Dev.
Min. Max.
Age (years) 46 0 67.98 9.96 45.47 88.25
H&Y 45 1 2.20 0.76 1.00 5.00
MoCA 45 1 26.04 2.47 18.00 30.00
UPDRS III 43 3 32.51 13.67 7.00 71.00
Disease duration
since diagnosis
(years)
45 1 7.07 4.37 1.00 20.00
MDT 1 sum score 46 0 3.63 2.35 −0.79 10.47
MDT 2 sum score 39 2 3.75 2.28 −0.76 8.63
MDT 3 sum score 35 3 3.68 2.05 0.16 8.63
H&Y, Hoehn and Yahr stage; MoCA, Montreal Cognitive Assessment; UPDRS III, Unified
Parkinson’s Disease Rating Scale part III; MDT 1-3 Munich Dysphagia Test—Parkinson’s
Disease (1 French version, first test; 2 French version, second test; 3 German version).
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Response and completion rate
FR1 was completed by all 46 patients, while FR2 was completed
by 41 subjects and GE by 38 of the initial group.
In FR2 and GE, the response rate (per test) was close to
100% for a majority of questions except Q22 and Q23 for FR2
and Q10, Q11, Q20, Q23, and Q25 for GE (cf. Supplement 3).
Consequently, weighted MDT-PD sum score could not be
evaluated in two patients for Fr2 and in three patients for GE due
to at least one missing item response (cf. Table 1).
Test-retest reliability
In order to analyze test-retest reliability, FR1 responses were
compared to FR2 responses.
The number of convergent responses was high in the first
test. Up to one-point difference was observed in 20 items and
for a high number of patients in item Q12 (n = 10), otherwise
for less than three patients in the other items (Q3, 4, 8, 15, 20,
and 21). Two points divergent responses were found for one to
two patients in items Q10, 11, 13, 14, 15, 20, and 22, as well as
three points divergent responses in items Q24, 25, and 26 (Note
that in items Q24–26 the response possibility was only bivariate
(yes/no) with zero or three points. A change in answer behavior at
one or two points difference was not possible. In contrast, items
Q1–23 had a four-point scale). No item differed in more than
three points.
Agreement between FR1 and FR2 was mis-evaluated with
Kappa for some questions due to zero cells and more than two
categories in the questions. In general, when the Kappa was
evaluated, it was in accordance with the KALPHA. There was no
dissymmetric evaluation.
Good agreement was found for Q21 for both Kappa (0.82)
and KALPHA (0.91). KALPHA was also higher than 0.8 for Q10
(0.84), Q15 (0.80), Q17 (0.84), and Q25 (0.89).
Moderate agreement was found for Q9 (0.77), Q20 (0.74),
and Q25 (0.77) with Kappa while only for Q24 (0.66) with
KALPHA. Details can be found in Supplement 4, Tables 4.1, 4.2
(item description cf. section Questionnaire Description).
The test-retest reliability in French language confirmed the
German language validation as shown by KALPHA (mean –
[range]= 0.52 – [0; 0.82] vs. 0.52 – [−0.05; 1]).
Language reliability
Concerning FR1 vs. GE, the divergent responses were less
important in number of patients concerned and therefore less
often compared to the two French versions, except for Q12.
Only disagreements with one-point difference (for 1–5 patients)
occurred in some cases as well as only four two-point differences
for a single patient each (Q11, 13, 14, and 22). Agreement
with KALPHA was very good except Q2, Q3, and Q24. Good
agreement as measured by the Kappa and KALPHA was showed
for Q4 (0.90 resp. 0.83), Q9 (0.84, resp. 0.84), Q10 (0.84 resp.
0.81), and Q25 (1.0 resp. 1.0). KALPHA was also of good
agreement for Q16 (0.85) as well as Kappa for Q26 (0.81).
Moderate agreement was concomitantly observed for Q20
(0.79 resp. 0.78), only with Kappa for Q11 (0.74), Q15 (0.73), and
Q23 (0.73) while only with KALPHA for Q18 (0.67). Details are
provided in Supplement 4, Tables 4.3, 4.4 (item description cf.
section Questionnaire Description).
Language reliability was found very good as demonstrated by
the KALPHA between the second French test and the original
German questionnaire (mean – [range]= 0.69 – [0; 1]).
For the comparison of FR2 with GE, divergent responses
occur less often between FR2 vs. GE compared with both French
versions. The number of convergent responses was high. Item
Q12 was again observed divergent at one difference in points for
four patients. Nine items were similarly divergent for one patient,
seven items for two patients and one for three patients. A three-
points difference was found in item 26 again (0/3 sale) for three
patients. The divergences seem lower than previously.
The agreement was generally very high, except for Q2 and
Q16. Especially good or excellent agreement was measured by
both Kappa and KALPHA (>0.8/1.0) for Q5, Q9, Q11, Q13, Q18,
Q19, Q23, and Q26; only by Kappa for Q1, Q6, Q15, Q22, Q2,
and only by Kalpha for Q4, Q8, Q10, and Q24.
Concordance for a good agreement was only observed with
Kappa for Q6 and Q22 and with KALPHA for Q8 and Q10.
For Q1, Q15, and Q25 the agreement was good with Kappa and
moderate with KALPHA, while for Q4 it was the opposite.
The agreement was moderate for Q12 for both Kappa and
KALPHA, for Q7 with Kappa only, and for Q14 and Q17 for
KALPHA. Details are given in Supplement 4, Tables 4.5, 4.6.
Figure 2 shows a graphical overview of strength in response
agreement of MDT-PD items for all test/language version
comparisons, and divided for KAPPA and KALPHA.
Internal consistency
The mean relative change between both French questionnaires
was below 20%, that can be interpreted as very good, except for
items Q12, Q22, and Q26. In general, the change was much lower
in comparison of FR2 to GE, while the comparison of the FR1
to GE showed slightly higher changes. Details for each item are
given in Supplement 5.
The Cronbach Alpha was evaluated globally and for the
deletion of one item4. With regard to the achieved internal
consistency of the original German study (0.91) (4), the overall
values for Cronbach Alpha in the present study was high as well,
meaning that the average correlation of items within the test
is good (0.80 in FR1, 0.84 in FR2, and 0.83 in GE). While the
variances of the items are low, the standardization of the items to
a standard deviation of 1 before computing the coefficient alpha
did not change it much andmaintaining its strength (0.84 for FR1
and 0.87 for GE).
The internal consistency was high both in terms of change
between items of the questionnaires and as evaluated by the
Cronbach Alpha overall and after deletion of one item (French
1 range = [0.77; 0.82], French 2 range = [0.82; 0.86], German
range= [0.80; 0.84]).
Most of the MDT-PD items (22/26) reached a Variance
Inflation Factor (VIF) value > 4 for almost one or even
for all three language versions demonstrating a strong
collinearity with some in particular: Q1 Chewing/swallowing
(up to 56.20), Q6 Food gets stuck (40.20), Q4 Multiple
swallowing (31.87), Q3 Swallowing trigger (18.81), Q17
4With a maximum of 1, 0.70 has been suggested as an acceptable, >0.8 as good,
and >0.9 as excellent reliability coefficient.
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FIGURE 2 | Strength in patients’ response agreement for MDT-PD items. The y-axis shows Kappa and Krippendorf Alpha coefficients for the different test-retest and
language reliability analyses (including French version 1 and 2, and German version); the x-axis contains the MDT-PD items (Munich Dysphagia Test–Parkinson’s
Disease, question 1–26). The bar of the histogram is not visible for a KAPPA/KALPHA value of 0.
Clearing throat (16.90), Q8 Coughing while drinking (15.31),
Q15 Off times (14.31), Q20 Rinsing afterwards (18.04),
Q19 Tiredness within meals (12.93), Q24 Lung infection
(12.34), Q25 Loss of weight (12.04), Q21 Single swallowing
(11.84), Q22 Loss of appetite (9.86), Q14 Pills (8.04), and
Q10 Changed voice (7.03). Further details are provided in
Table 5.4 of the Supplement 5. Bivariate correlation calculation
for all MDT-PD items revealed a plurality of moderately
positive correlations (t > 0.40). Corresponding correlograms
for MDT-PD versions FR1, FR2, and GE are shown in
Supplement 5, Figure 5.1.
Construct validity
No significant difference between diagnoses of parkinsonism
(including PD, PD with dementia, PSP, CBS, VP, and unspecified
parkinsonism) were found for FR1, as the mean MDT total score
was ranging from 2 to 5 with an outlier at 7.5 (Cerebrovascular
disease with PD features) (p = 0.39). Furthermore, we did not
find any difference for FR2 (p = 0.2) nor for GE (p = 0.71)
between the different forms of parkinsonism.
Moreover, no significant difference between H&Y stages were
found for FR1, as means were included in the interval 2.5–5
except for an H&Y stage 3 with a higher variability (four patients
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concerned). The distribution of means was homogeneous with p
= 0.73. Concerning FR2 and GE, the means were also similarly
distributed in the different H&Y stages (p = 0.81 and p =
0.99, respectively).
No significant relationships ofMDT-PD scores were found for
theMoCA score (FR1: R2 = 0.017, p= 0.39; FR2: R2 = 0.021, p=
0.38; GE: R2 = 0.032, p= 0.31), theMDS-UPDRS III score (FR1:
R2 = 0.007, p= 0.59; FR2: R2 = 0.0007, p= 0.88; GE: R2 = 0.014,
p= 0.51) or disease duration (FR1: R2 = 0.022, p= 0.32; FR2: R2
= 0.0002, p= 0.93; GE: R2 = 0.004, p= 0.69).
The categorization of the disease duration in 5<, 5–10, and
>10 y has not led to significant results concerning the effect on
the MDT scores at the first, second and third evaluations.
Detailed tables and figures for all clinical parameters assessed
are given in Supplement 6.
DISCUSSION AND CONCLUSION
Based on the results, we were able to create a new language
version of the MDT-PD questionnaire in French with very
good test-retest and language reliability as well as high internal
consistency that can be used as a non-invasive tool for early
detection of dysphagia and aspiration risk and will be valuable
when implementing novel prevention strategies addressing the
French speaking population.
With respect to the currently over 220million French speakers
worldwide, including 72million so-called partial French speakers
(expected to rise to>700 million in 2050 as a result of population
growth after estimation of the Organization Internationale de
la Francophonie), French is an official language in 29 countries
and the sixth most widely spoken language after Mandarin
Chinese, English, Hindi, Spanish and Arabic (and the second
common language in Europe). At the same time, PD is the
second most common age-related neurodegenerative disorder
just after Alzheimer’s disease with an estimate of approximately
seven million people affected worldwide and still exponentially
increasing beyond the aging populations with an estimated
doubling until 2040 (21). In addition, pneumonia, especially
due to dysphagia with aspiration is considered to be the
leading cause of mortality in all forms of parkinsonism (22,
23). Considering all of the above mentioned, a screening tool
allowing to detect dysphagia in French speaking PD patients
becomes indispensable.
Response rate was high at all three MDT-PD tests, and
only a few patients dropped out between the tests. The
extent of response agreement was globally high, with a
majority of up to one-point difference. However, the item
Q12 (reflecting a reduced salivation/feeling of dry mouth)
showed consistent divergence. This might be due to the variable
symptom fluctuation depending on hydration, temperature and
momentary diet, which might explain that patients are not
consistently responding to this item from one time point to
another. For the comparison between the French and German
MDT-PD version agreement within questionnaire items was
generally higher than for both French versions (especially
regarding 2–3 points divergence).
We assume that the chosen interval for MDT-PD completion
dates (5–7 days) was optimal and also long enough to exclude
that the answers on previous versions can be immediately
remembered. In the literature test-retest intervals for PD related
instruments/questionnaires usually vary between 2 days up to
>1 month without any statistically significant difference, but
slightly higher values for 14 days or less (17). Even if we may
not suspect a learning effect per se in this type of questionnaire
(as this is the case in cognitive tests), it might be possible that
patients may want to respond consistently from one to another
time point. The other way around, a maximum limit of 7 days
between two test completions was intended to prevent an answer
behavior completely different to the previous test due to changes
in the disease condition, e.g., progression of axial symptoms. In
addition, there was no modification of medication during the
study period.
More generally (and related toQ15), swallowing improvement
due to dopaminergic medication is controversially discussed.
Although levodopa responsiveness of dysphagia symptoms was
formerly considered negligible (24, 25), there are more recent
studies showing (short-term) changes in swallowing performance
due to oral L-Dopa-intake, subcutaneous apomorphine
application, or transdermal rotigotine delivery in some patients
(26–29).
In the literature it is presumed that the gastrointestinal system
does play a multifaceted role in PD, beginning with the presence
of pervasive α-synuclein deposition in the gastrointestinal
tract that is involved in the pathogenesis of the disease,
and ending with implications of the system affecting several
complications including drooling and swallowing problems (30).
This implicates the high priority of future studies elucidating the
role of the gastrointestinal system on the pathological progression
of PD. While it is estimated that the majority of dysphagic PD
patients are at progressed disease stage, there are few studies
discussing dysphagia as an early symptom, prodromal or even
the first sign of PD. Nevertheless, early, severe dysphagia is
considered to be more relevant in the Parkinsonian variant of
MSA (MSA-P) (31).
For FR1 37% of study patients has been identified as dysphagia
positive by the weighted MDT-PD screening questionnaire (41%
for FR2 and 46% for GE). Table 2 shows the distribution of
dysphagia severity assessed by MDT-PD for all three language
versions in patients with PD and aPS (additional tables
containing distribution and descriptive statistics of MDT-PD
score characteristics is provided in Supplement 7). Although
these rates are similar to the relatively low percentage of PD
patients subjectively complaining about swallowing problems in
comparison to objectively assessed dysphagia via instrumental
diagnostic approaches as shown in other studies (1, 32,
33), this is an unexpected high rate with regard to the
very mild disease stage in the present study (mean H&Y
of 2.2).
Given the fact that there was no significant correlation
between the MDT-PD score and characteristics of investigated
clinical parameters (disease stage, disease duration, motor
functions, cognitive performance or diagnose of parkinsonism),
we are confident to pursue the hypothesis that dysphagia
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TABLE 2 | Distribution of dysphagia positive/negative screened patients by MDT-PD, separated for patients with PD and aPD.
MDT-PD
questionnaire
MDT-PD score PD Proportion from the
participant group (%)
aPS +
secondary PS
Proportion from the
participant group (%)
All cohort (PD + aPS
+ secondary PS)
Proportion from the
cohort (%)
FR1 N 39 100 7 100 46 100
<3.65 26 67 3 43 29 63
≥3.65 5 13 2 28.5 7 15
≥4.79 8 20 2 28.5 10 22
FR2 N 34 100 5 100 39 100
<3.65 21 62 2 40 23 59
≥3.65 3 9 1 20 4 10
≥4.79 10 29 2 40 12 31
GE N 31 100 4 100 35 100
<3.65 18 58 1 25 19 54
≥3.65 4 13 3 75 7 20
≥4.79 9 29 0 0 9 26
<3.65 No noticeable dysphagia;≥3.65 Noticeable, oropharyngeal dysphagia;≥4.79 Dysphagia with risk of aspiration; Munich Dysphagia Test—Parkinson’s Disease, MDT-PD (FR1/FR2,
French version test 1/2; GE, German version); PD, Parkinson’s disease; aPS, atypical parkinsonian syndrome; absolute numbers of patients (percentages considering the relative
proportions for PD vs. aPS vs. total cohort). Bold values represents total number of values per group.
could be considered as an early symptom in both PD
and aPS.
While using the French version of the MDT questionnaire we
were not able to show distinctive frequencies of patients with
dysphagia between the different types of parkinsonism or the
different levels ofmotor disease progression tested (Hoehn&Yahr,
UPDRSIII, disease duration). According to the analyses carried
out so far, it did not discriminate different level of disease or
symptoms. It could be a consequence of the small sample size
especially in the sub groups, as the majority of participants were
idiopathic PD patients. But given the fact that the underlying
mechanism of dysphagia progression are still unclear, the
present results of the correlation analyses thus assume particular
significance. However, the original German questionnaire was
designed for the detection of noticeable dysphagia for early
stage of PD and an Anova analysis of 38 idiopathic PD patients
provided similar results for each variable, where the construct
validity was tested (4). Therefore, construct validity should be
further explored as the sample used in the current research
may not be heterogeneous enough. This is currently tested in
our subsequent diagnostic validation study as well as for other
language translations/cultural adaptations of the MDT-PD.
Usually, dysphagia is associated with clinical parameters
like higher H&Y stage, relevant loss of body weight,
drooling/sialorrhea, or dementia (6). The increasing of
swallowing impairment with disease stage therefore has
been expected, but even significant dysphagia symptoms with
penetration or aspiration for at least one consistency has been
observed in early PD stages with H&Y of 2 or lower among
other recent cohort studies (34). Regarding the association
between cognitive impairment and dysphagia we are aware
of the fact, that we excluded study subjects with MoCA <17
toward securing deep comprehension performance and assume
a positive correlation under real-life conditions.
In general, early screening for dysphagia should be taken
into consideration in neurological point of care to enable
identification of swallowing impairments including the very
early oropharyngeal symptoms and particularly to prevent
severe clinical complications or threats to health as well as
to quality of life. For sure, there is a limitation for the
usage of the MDT-PD questionnaire in daily practice among
PD patients with severe dementia or severe depression as
these cognitive and neuropsychological states may have a
negative influence on the answering behavior and also for
the prediction of the test result. The ability of adequately
comprehending and answering questionnaire items should be
tested therefore prior to the completion of patient-centered,
self-reported questionnaires.
In contrast to a recently published clinical study where among
others, mismatched parameter classifications were unfortunately
applied for the comparison between the three different MDT-
PD categories and the dysphagia estimations based on a single
diagnostic parameter only (penetration-aspiration scale for the
consistency water, PAS H2O; more details are provided in
Supplement 8) (35), the results of this project, being in line
with a simultaneously completed study validating the new Italian
version of MDT-PD. These findings underline both the very
good psychometric properties of the patient questionnaire and
its ability to discriminate between “non-dysphagic” PD patients
and dysphagic individuals with “any oropharyngeal symptoms,”
or even with “risk of aspiration.” In addition, the strong positive
correlation between MDT-PD score and FEES results (incl. PAS
H2O only) was reconfirmed.
Subsequently, the hypothesis above will be further addressed
by the follow-up diagnostic validation of the French MDT-PD
version, where all included patients with diagnosed parkinsonism
and positively screened by the MDT-PD questionnaire will
undergo CSA and FEES (cf. Figure 1, phase 3) complying
standardized and Parkinson-specific protocols (4). Following this
promising first phases, clinical examinations consisting of CSA
and FEES should enable us to verify the diagnostic quality of the
French MDT-PD.
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